Rob Abbott – CEO, ISPOR
Rob Abbott, CEO of ISPOR—The Professional Society for Health Economics and Outcomes Research (ISPOR) provides an update on the organisation’s activities since taking up the role in 2023, including the…
ABBOTT LABORATORIES is an American-based, global, diversified healthcare firm. Among the world’s largest and most successful corporations, ABBOTT has a presence in more than 160 countries.
Cardiovascular
Diabetes
Diagnostics
Nutrition
Neuromodulation
Pharmaceuticals
Contact:
Address: Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064
Tel: (224) 667-6100
Rob Abbott, CEO of ISPOR—The Professional Society for Health Economics and Outcomes Research (ISPOR) provides an update on the organisation’s activities since taking up the role in 2023, including the…
Marion Allerstorfer, General Manager of Abbott’s diabetes care business in Switzerland and Austria, shares insights from her two-decade career at the company, highlighting Abbott’s strong people-first culture and its ability…
Well-informed and data-driven healthcare decision making has never been more important. Healthcare systems across the world – in both developed and developing contexts – are grappling with the challenge of…
General manager of Core Diagnostic at Abbott Turkey Yelda Ulu Colin highlights the company’s prominent role during the pandemic, including the launch of the first antibody serology testing solution just…
Mohamed Benali Khoudja, GM for the Francophone Africa cluster at Abbott reveals the rationale behind creating a country cluster, discusses the market for local CMOs in Algeria, and expands on…
A passionate advocate for reverse mentoring, Abbott India Limited’s managing director, Venu Ambati, discusses the productive investments that the company has made in India, and his intention to make digital…
The General Manager of Abbott’s Established Pharmaceuticals Division in South Africa, Gauta Phillip Mavundla illustrates how he is building the division’s presence within the region after the spinoff of AbbVie,…
Abbott has been in Indonesia for roughly 42 years already. Over this time, has the affiliate managed to reach a positioning similar to that of the Group globally, or is…
Ms Joubert, could you start by telling our readers over the 16 months of heading the operations here, what have been the most challenging situations as the General Manager of…
You took over as GM back in 2008. No doubt that this was a challenging time to run a business, in particular in view of the external economic environment. Can…
PwC’s Kelly Barnes examines how the US pharmaceutical sector is having to rethink its relationship with consumers, experimenting with new and innovative pricing models, and adopting a more holistic view…
Eurasia Group’s Aditya Bhattacharji looks at the potentially damaging fallout of the ongoing US-China trade war on the life sciences industry. Biotech [is the] new frontier for US-China tensions…
Christopher P. Molineaux of Life Sciences Pennsylvania outlines the Keystone State’s rich lineage of pharmaceutical innovation, how the association is building inter-state and international connections, and why Philadelphia is justified…
Chip Davis of the Association for Accessible Medicines argues that learning from the European biosimilars approval experience could speed up patient access to these complex drugs in the USA. …
US industry veteran Sharon Ayd describes her journey to becoming a pharma company board member, the various hurdles still facing female pharma executives, and the responsibility of women at the…
A new white paper from Fasken law firm asserts that the early filing of patents for innovative products is crucial for companies hoping to succeed in the booming North American…
Meghann Chilcott offers an introductory look at the potential of customer data platforms (CDPs) to transform the way pharmacy marketers reach out to an increasingly online customer base in the…
Carla Smith outlines the role that a value-based care (VBC) approach can have on both reducing healthcare costs and improving overall care delivery to patients in the USA. Smith highlights…
David Bearman makes the historical case to be once again considered as a medicine across the USA, noting that economic – rather than health – concerns were behind the creation…
Chip Davis is head of the Association for Accessible Medicines (AAM) which advocates for greater uptake of generic and biosimilar drugs in the USA. Here, Davis argues that the generics…
Monica Weldon looks at the history of medicinal CBD, its current usages in the USA, and why robust scientific research on its efficacy need to be conducted in order to…
An examination of the evolution of the pharma data supply chain and the vital importance of establishing trust with patients to access complete information sets from Matt Sinderbrand, formerly CEO…
See our Cookie Privacy Policy Here
